What are organoids ?

Organoids are in vitro models of organs generated from stem or progenitor cells that self‑organize into structured, tissue‑like architectures. They are grown in 3D culture where the cells aggregate, establish intercellular adhesion, and undergo lineage‑specific differentiation. By doing so, they recapitulate key morphological and functional traits of tissues found in the body. Because organoids preserve the intrinsic biological characteristics of their cells of origin, including genetic, epigenetic, and phenotypic identities, they serve as highly accurate models of native tissue architecture and physiology.

Organoid generation and types

The starting cell population is a key determinant of both the morphological and functional traits of an organoid.

Normal organoids such as cerebral, retinal, lung, kidney, and cardiac models are derived from healthy tissue stem cells or pluripotent stem cells and follow intrinsic developmental programs by maintaining defined polarity, regulated signalling, and organized tissue architecture, enabling the study of early organogenesis. Epithelial organoids, which are derived from adult stem cells, include intestinal, gastric, pancreatic ductal, liver, prostate, and mammary gland systems and recapitulate the epithelial tissue architecture.

Cancer spheroids are simple tumor models formed by aggregating cancer cells in 3D culture. They lack tissue organization and primarily reflect bulk tumor characteristics such as hypoxic gradients and heterogeneous proliferation.

In contrast, cancer organoids generated from tumor stem or initiating cells obtained from patient biopsies recapitulate malignant traits while preserving their genetic alterations and clonal heterogeneity,

Finally, multilineage organoids or assembloids, formed by fusing distinct organoid types (eg cortical–thalamic combinations), enable investigation of higher‑order interactions, circuit formation, and cross‑tissue communication that cannot be captured in single‑lineage models.

Major uses of organoids

Organoids have emerged as powerful tools in biomedical research as a model for preclinical studies.

In disease modeling, organoids generated from patient‑derived iPSCs or primary tissues enable researchers to investigate genetic disorders, developmental defects, and infectious diseases, including enteric viral infections and SARS‑CoV‑2, within organ‑specific systems.

Organoids have become key tools in oncology research, providing more realistic models for evaluating therapeutic efficacy and toxicity. Patient‑derived organoids, in particular, are now widely used to personalise therapy by modelling individual tumour responses to candidate drugs.

In regenerative medicine, organoids serve as building blocks for tissue engineering and transplantation research, such as studies on intestinal crypt repair and liver bud formation.  They also provide powerful systems for probing organ development by modelling organogenesis and uncovering the molecular mechanisms that regulate tissue formation.

Additionally, organoids provide powerful platforms for dissecting microenvironmental signals and host–pathogen interactions; when co‑cultured with immune cells, they enable detailed examination of epithelial–immune crosstalk. Together, these advantages make organoids indispensable tools for deepening our understanding of human biology, revealing disease mechanisms, and accelerating therapeutic development.

How organoids differ from traditional cell and animal models

Biomedical research has long depended on a few model organisms, chosen because they are robust, fast‑growing, produce large numbers of offspring, and can be maintained inexpensively in the laboratory. Their extensive characterization, encompassing well‑documented development and physiology, established experimental methodologies, and extensive resources such as reagents and curated databases, provides a strong foundation for research.

Organoids complement and extend these traditional models by closely recapitulating the architecture, spatial organization, and functional characteristics of human organs and tissues in vitro. This helps overcome major limitations of conventional models and narrows the gap between laboratory studies and real human biology.

Why is imaging essential in organoid research?

Evaluating organoid morphology is key to judging how well a culture replicates its native tissue or organ. The specific structural traits to assess depend on the organ system being modelled. In secretory tissues like pancreatic islets, organoids should form spherical, islet‑like structures and contain detectable hormone‑filled vesicles. Branching epithelial organoids, such as those from the mammary gland, are expected to develop clear branched morphologies, while intestinal organoids should display defined crypt‑like regions.

In more complex organoid systems that include stromal or endothelial support cells, the endothelial component should form vascular‑like networks that reflect native endothelial–epithelial interactions. Morphology should always be compared against freshly isolated tissues, which provide the reference standard for structural accuracy. Assessing cellular identity also involves staining for proteins that vary across specific layers or regions, along with analyzing cell composition, spatial arrangement, proportions of different cell types, and the maturation states of each subpopulation.

What are the main imaging approaches?

Imaging is critical for organoid research because organoids are three‑dimensional, multicellular structures whose development, spatial organization, and functional states cannot be assessed without appropriate visualization techniques.

Brightfield microscopy is commonly used for routine monitoring of 3D organoids in culture, and when combined with antibody‑based immunohistochemistry (IHC), it enables detailed assessment of organoid growth, cellular composition, and overall morphology. Confocal microscopy enables high‑resolution, optically sectioned fluorescence imaging for detailed 3D structural, antibody‑staining, and reporter‑based analyses. Light‑sheet fluorescence microscopy (LSFM) is well suited for whole‑organoid imaging due to its rapid acquisition, low phototoxicity, and ability to capture dynamic developmental events in systems like brain or retinal organoids. Two‑photon microscopy provides deeper imaging with reduced photodamage, making it ideal for large, intact organoids.

For large‑scale studies, high‑content imaging combines automated microscopy with computational analysis to enable standardized, high‑throughput assessment in drug‑screening workflows involving many organoids. Effective imaging also depends on proper sample preparation, including optical clearing to improve light penetration in thick specimens and fixation/permeabilization for antibody‑based assays.

Why IHC matters for organoid models

In organoid studies, IHC serves multiple, complementary purposes.

• It establishes identity and fidelity by confirming that the model recapitulates target tissue architecture and lineage features.
• Standardized IHC panels support consistent quality control, help detect batch‑to‑batch variation, and enhance reproducibility across laboratories
• By providing spatial and subcellular context, IHC pinpoints proteins in situ, revealing features such as polarity, lumen formation, basement‑membrane organization, and intracellular compartmentalization.
• IHC also uncovers cellular heterogeneity by visualizing micro‑niches, gradients, and rare cell populations that bulk assays cannot detect.
• IHC supports tracking differentiation and maturation by revealing cell‑state composition, proliferation, and apoptosis, offering a sensitive readout of how culture conditions or protocol changes affect organoid development.
• For disease‑modelling applications, IHC confirms clinically relevant phenotypes and verifies key histopathological features.
• As a mechanism‑of‑action readout, it provides spatially resolved visualization of pharmacodynamic signals that clarify treatment responses and resistance niches.
• As an orthogonal validator of omics, IHC corroborates transcriptomic findings at the protein and post‑translational levels.
• Because IHC is compatible with FFPE‑based clinical workflows, it enables direct comparison with patient biopsy samples and supports translational biomarker development.
• In regulatory and biobanking settings, IHC provides fit-for-purpose release criteria and creates an auditable record of model identity and quality.

Optimizing chromogenic IHC in organoids: when to use single vs multiplex panels

In organoid workflows, the choice between single‑plex and multiplex chromogenic IHC should be based on the experimental purpose, sample availability, and whether spatial co‑expression needs to be visualized.

Chromogenic IHC maintains native histopathological structure and brightfield contrast, allowing direct, like-for-like comparison with parental tissues and clinical reference samples. In contrast, immunofluorescence, especially in cleared or densely labelled specimens, aligns less closely with standard diagnostic morphology.

Single‑plex chromogenic IHC is the modality of choice for robust quality control, high throughput, and clinical comparability, as it is rapid to optimise, straightforward to standardise, and highly reproducible across batches and sites.

Multiplex chromogenic IHC (2–4 markers) is suitable when cell‑level co‑expression must be assessed on the same section, when conserving limited tissue is important, or when mapping mixed cell states with histological context in brightfield is required. For panels with more than four markers or for precise subcellular co‑localization, multiplex immunofluorescence is preferable because chromogenic colour separation and dynamic range become limiting beyond roughly 3–4 targets.

For organoids specifically, chromogenic IHC is typically performed on formalin‑fixed paraffin‑embedded sections (3–4 µm), with whole‑mount preparations better suited to immunofluorescence and confocal imaging; multiplexing helps conserve scarce sections and reveal heterogeneity and micro‑niches that serial sections may miss.

References

1.      Zhao Z, Chen X, Dowbaj AM, Sljukic A, Bratlie K, Lin L, Fong ELS, Balachander GM, Chen Z, Soragni A, Huch M, Zeng YA, Wang Q, Yu H. Organoids. Nat Rev Methods Primers. 2022;2:94. doi: 10.1038/s43586-022-00174-y. Epub 2022 Dec 1. PMID: 37325195; PMCID: PMC10270325.

2.      Liu X, Zhou Z, Zhang Y, Zhong H, Cai X, Guan R. Recent progress on the organoids: Techniques, advantages and applications. Biomed Pharmacother. 2025 Apr;185:117942. doi: 10.1016/j.biopha.2025.117942. Epub 2025 Mar 4. PMID: 40043462.

3.      Artegiani B, Hendriks D. Organoids from pluripotent stem cells and human tissues: When two cultures meet each other. Dev Cell. 2025 Feb 24;60(4):493-511. doi: 10.1016/j.devcel.2025.01.005. PMID: 39999776.

4.      Kim J, Koo BK, Knoblich JA. Human organoids: model systems for human biology and medicine. Nat Rev Mol Cell Biol. 2020 Oct;21(10):571-584. doi: 10.1038/s41580-020-0259-3. Epub 2020 Jul 7. PMID: 32636524; PMCID: PMC7339799.

5.      Wahle P, Brancati G, Harmel C, He Z, Gut G, Del Castillo JS, Xavier da Silveira Dos Santos A, Yu Q, Noser P, Fleck JS, Gjeta B, Pavlinić D, Picelli S, Hess M, Schmidt GW, Lummen TTA, Hou Y, Galliker P, Goldblum D, Balogh M, Cowan CS, Scholl HPN, Roska B, Renner M, Pelkmans L, Treutlein B, Camp JG. Multimodal spatiotemporal phenotyping of human retinal organoid development. Nat Biotechnol. 2023 Dec;41(12):1765-1775. doi: 10.1038/s41587-023-01747-2. Epub 2023 May 8. PMID: 37156914; PMCID: PMC10713453.

6.      Miller G, Lloyd-Davies Sánchez DJ, González Martínez J, Justin AW, Lancaster MA, Guglielmi L. Organizers in a dish: Modeling human CNS morphogenesis. Dev Cell. 2026 Feb 11;61(2):240-258. doi: 10.1016/j.devcel.2026.01.003. Epub 2026 Feb 4. PMID: 41643664.

7.      Dijkstra KK, Monkhorst K, Schipper LJ, Hartemink KJ, Smit EF, Kaing S, de Groot R, Wolkers MC, Clevers H, Cuppen E, Voest EE. Challenges in Establishing Pure Lung Cancer Organoids Limit Their Utility for Personalized Medicine. Cell Rep. 2020 May 5;31(5):107588. doi: 10.1016/j.celrep.2020.107588. PMID: 32375033.

8.      Dijkstra KK, Monkhorst K, Schipper LJ, Hartemink KJ, Smit EF, Kaing S, de Groot R, Wolkers MC, Clevers H, Cuppen E, Voest EE. Challenges in Establishing Pure Lung Cancer Organoids Limit Their Utility for Personalized Medicine. Cell Rep. 2020 May 5;31(5):107588. doi: 10.1016/j.celrep.2020.107588. PMID: 32375033.

9.      Salahudeen AA, Choi SS, Rustagi A, Zhu J, van Unen V, de la O SM, Flynn RA, Margalef-Català M, Santos AJM, Ju J, Batish A, Usui T, Zheng GXY, Edwards CE, Wagar LE, Luca V, Anchang B, Nagendran M, Nguyen K, Hart DJ, Terry JM, Belgrader P, Ziraldo SB, Mikkelsen TS, Harbury PB, Glenn JS, Garcia KC, Davis MM, Baric RS, Sabatti C, Amieva MR, Blish CA, Desai TJ, Kuo CJ. Progenitor identification and SARS-CoV-2 infection in human distal lung organoids. Nature. 2020 Dec;588(7839):670-675. doi: 10.1038/s41586-020-3014-1. Epub 2020 Nov 25. PMID: 33238290; PMCID: PMC8003326.

10.  Gjorevski N, Sachs N, Manfrin A, Giger S, Bragina ME, Ordóñez-Morán P, Clevers H, Lutolf MP. Designer matrices for intestinal stem cell and organoid culture. Nature. 2016 Nov 24;539(7630):560-564. doi: 10.1038/nature20168. Epub 2016 Nov 16. PMID: 27851739.

11.  Zakrzewski W, Dobrzyński M, Szymonowicz M, Rybak Z. Stem cells: past, present, and future. Stem Cell Res Ther. 2019 Feb 26;10(1):68. doi: 10.1186/s13287-019-1165-5. PMID: 30808416; PMCID: PMC6390367.

12.  Sato T, Vries RG, Snippert HJ, van de Wetering M, Barker N, Stange DE, van Es JH, Abo A, Kujala P, Peters PJ, Clevers H. Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche. Nature. 2009 May 14;459(7244):262-5. doi: 10.1038/nature07935. Epub 2009 Mar 29. PMID: 19329995.

13.  Kim M, Mun H, Sung CO, Cho EJ, Jeon HJ, Chun SM, Jung DJ, Shin TH, Jeong GS, Kim DK, Choi EK, Jeong SY, Taylor AM, Jain S, Meyerson M, Jang SJ. Patient-derived lung cancer organoids as in vitro cancer models for therapeutic screening. Nat Commun. 2019 Sep 5;10(1):3991. doi: 10.1038/s41467-019-11867-6. PMID: 31488816; PMCID: PMC6728380.

14.  Zushin PH, Mukherjee S, Wu JC. FDA Modernization Act 2.0: transitioning beyond animal models with human cells, organoids, and AI/ML-based approaches. J Clin Invest. 2023 Nov 1;133(21):e175824. doi: 10.1172/JCI175824. PMID: 37909337; PMCID: PMC10617761.

15.  Lancaster MA, Knoblich JA. Organogenesis in a dish: modeling development and disease using organoid technologies. Science. 2014 Jul 18;345(6194):1247125. doi: 10.1126/science.1247125. Epub 2014 Jul 17. PMID: 25035496.

16.  Fujii M, Matano M, Toshimitsu K, Takano A, Mikami Y, Nishikori S, Sugimoto S, Sato T. Human Intestinal Organoids Maintain Self-Renewal Capacity and Cellular Diversity in Niche-Inspired Culture Condition. Cell Stem Cell. 2018 Dec 6;23(6):787-793.e6. doi: 10.1016/j.stem.2018.11.016. PMID: 30526881.

17.  Giandomenico SL, Sutcliffe M, Lancaster MA. Generation and long-term culture of advanced cerebral organoids for studying later stages of neural development. Nat Protoc. 2021 Feb;16(2):579-602. doi: 10.1038/s41596-020-00433-w. Epub 2020 Dec 16. PMID: 33328611; PMCID: PMC7611064.

18.  Roper SJ, Linke F, Scotting PJ, Coyle B. 3D spheroid models of paediatric SHH medulloblastoma mimic tumour biology, drug response and metastatic dissemination. Sci Rep. 2021 Feb 19;11(1):4259. doi: 10.1038/s41598-021-83809-6. PMID: 33608621; PMCID: PMC7895940.

19.  Dinevska M, Widodo SS, Mantamadiotis T. High-Throughput Multiplex Immunohistochemistry of Glioma Organoids. Methods Mol Biol. 2024;2746:57-65. doi: 10.1007/978-1-0716-3585-8_4. PMID: 38070079.

20.  Hickey JW, Neumann EK, Radtke AJ, Camarillo JM, Beuschel RT, Albanese A, McDonough E, Hatler J, Wiblin AE, Fisher J, Croteau J, Small EC, Sood A, Caprioli RM, Angelo RM, Nolan GP, Chung K, Hewitt SM, Germain RN, Spraggins JM, Lundberg E, Snyder MP, Kelleher NL, Saka SK. Spatial mapping of protein composition and tissue organization: a primer for multiplexed antibody-based imaging. Nat Methods. 2022 Mar;19(3):284-295. doi: 10.1038/s41592-021-01316-y. Epub 2021 Nov 22. PMID: 34811556; PMCID: PMC9264278.

21.  Chiaradia I, Lancaster MA. Brain organoids for the study of human neurobiology at the interface of in vitro and in vivo. Nat Neurosci. 2020 Dec;23(12):1496-1508. doi: 10.1038/s41593-020-00730-3. Epub 2020 Nov 2. PMID: 33139941.